Skip to Main Content (Press Enter)

Logo UNIMORE
  • ×
  • Home
  • Degree programmes
  • Modules
  • Jobs
  • People
  • Research Outputs
  • Academic units
  • Third Mission
  • Projects
  • Skills

UNI-FIND
Logo UNIMORE

|

UNI-FIND

unimore.it
  • ×
  • Home
  • Degree programmes
  • Modules
  • Jobs
  • People
  • Research Outputs
  • Academic units
  • Third Mission
  • Projects
  • Skills
  1. Research Outputs

Side Effects of Immunosuppressant Drugs After Liver Transplant

Academic Article
Publication Date:
2025
Short description:
Side Effects of Immunosuppressant Drugs After Liver Transplant / Gabrielli, F.; Bernasconi, E.; Toscano, A.; Avossa, A.; Cavicchioli, A.; Andreone, P.; Gitto, S.. - In: PHARMACEUTICALS. - ISSN 1424-8247. - 18:3(2025), pp. 1-30. [10.3390/ph18030342]
abstract:
Liver transplantation (LT) is the standard of care for both end-stage liver failure and hepatocellular carcinoma (HCC). Side effects of the main used immunosuppressive drugs have a noteworthy impact on the long-term outcome of LT recipients. Consequently, to achieve a balance between optimal immunosuppression and minimal side effects is a cornerstone of the post-LT period. Today, there are no validated markers for overimmunosuppression and underimmunosuppression, only a few drugs have therapeutic drug monitoring, and immunosuppression regimens vary from center to center and from country to country. Currently, there are many drugs with different efficacy and safety profiles. Using different agents permits a decrease in the dosage and minimizes the toxicities. A small subset of recipients achieves immunotolerance with the chance to stop immunosuppressive therapy. This article focuses on the side effects of immunosuppressive drugs, which significantly impact long-term outcomes for LT recipients. The primary aim is to highlight the balance between achieving effective immunosuppression and minimizing adverse effects, emphasizing the role of personalized therapeutic strategies. Moreover, this review evaluates the mechanisms of action and specific complications associated with immunosuppressive agents. Finally, special attention is given to strategies for reducing immunosuppressive burdens, improving patient quality of life, and identifying immunotolerant individuals.
Iris type:
Articolo su rivista
Keywords:
MASLD; cardiovascular disease; frailty; immunosuppression; metabolic syndrome; nephrotoxicity; orthotopic liver transplant; osteoporosis; side effect; tacrolimus
List of contributors:
Gabrielli, F.; Bernasconi, E.; Toscano, A.; Avossa, A.; Cavicchioli, A.; Andreone, P.; Gitto, S.
Authors of the University:
Gabrielli Filippo
Handle:
https://iris.unimore.it/handle/11380/1377889
Full Text:
https://iris.unimore.it//retrieve/handle/11380/1377889/895083/pharmaceuticals-18-00342-v2.pdf
Published in:
PHARMACEUTICALS
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.4.5.0